| E.1 Medical condition or disease under investigation |
| E.1.1 | Medical condition(s) being investigated |
| Chronic Hepatitis C infected patient |
|
| E.1.1.1 | Medical condition in easily understood language |
|
| E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
| MedDRA Classification |
| E.1.3 | Condition being studied is a rare disease | No |
| E.2 Objective of the trial |
| E.2.1 | Main objective of the trial |
The following objectives applies to Part A and Part B of the study:
1. Objective: To evaluate the effectiveness of the combination regimens of MK-5172 and MK-3682 (300 mg or 450 mg) with either MK-8742 (Part A only) or MK-8408 as assessed by the proportion of subjects in each group achieving undetectable levels of Hepatitis C virus (HCV) RNA levels in the blood 12 weeks after the end of all study therapy.
2. Objective: To evaluate the safety and tolerability (how well the subject can tolerate the side effects) of the combination regimens of MK-5172 and MK-3682 (300 mg and 450 mg) with either MK-8742 (Part A only) or MK-8408 to subjects in each arm |
|
| E.2.2 | Secondary objectives of the trial |
The following applies to Part A and Part B (unless otherwise specified):
1. Objective: To evaluate the effectiveness of the combination regimens of MK-5172 and MK-3682 (300 mg and 450 mg) with either MK-8742 (Part A only) or MK-8408 as assessed by the proportion of subjects in each group achieving undetectable levels of Hepatitis C virus (HCV) RNA levels in the blood 24 weeks after the end of all study therapy.
In Part B:
2. Objective: Among HIV-1 co-infected patients, to evaluate the proportion of subjects who develop HIV-1 virologic failure (HIV-1 RNA 200 copies/mL, confirmed on two consecutive tests at least 2 weeks apart, in subjects compliant with their HIV antiretroviral therapy [ART]).
3. Objective: Among HCV/HIV-1 co-infected patients, to evaluate the effect of the study regimens on CD4+ T-cell counts.
|
|
| E.2.3 | Trial contains a sub-study | Yes |
| E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Merck will conduct Future Biomedical Research on blood specimens (leftover DNA, leftover plasma) collected during this clinical trial. Such research is for tests to address emergent questions not described elsewhere in the protocol (as part of the main trial) and will only be conducted on specimens from appropriately consented subjects. The objective of collecting specimens for Future Biomedical Research is to find out more about what causes disease and the differences in the way that people respond to drugs and therapies. The overarching goal is to use such information to develop safer, more effective drugs, and/or to ensure that subjects receive the correct dose of the correct drug at the correct time.
Intensive Viral Kinetic Sub-study:
A subgroup of the study population will be included in an intensive viral kinetic sub-study. This is optiomal and only those patients who agree and sign a seperate consent to take part in the intensive viral kinetic sub-study will be included. The purpose of this sub-study is to determine whether early viral kinetics can aid in developing a PK/PD model that can predict combinations which may be efficacious with shorter treatment durations.
These subjects will have HCV RNA samples collected during Week 1 as described in the Study Flow Chart (Section 6.0) and in Table 15 (Intensive Viral Kinetic Week 1 Sampling Timepoints). In addition, PK samples will be collected as described in Table 13 (Pharmacokinetic Sampling Timepoints). These samples will be used to evaluate the PK/PD relationships of MK-5172, MK-3682 (and metabolites), MK-8742, and MK-8408, as appropriate.
|
|
| E.3 | Principal inclusion criteria |
The following applies to Part A & B unless specified:
1.be ≥18 years
2.HCV RNA (≥ 10,000 IU/mL in peripheral blood) at screening.
3. Have documented chronic HCV GT3 (with no evidence of non-typeable or mixed genotype) infection:
•Positive for anti-HCV antibody, HCV RNA, or HCV genotype 3 at least 6 months before screening, or at the time of screening with a liver biopsy consistent with chronic HCV infection
4.Be otherwise healthy as determined by the medical history, physical examination, ECG, and clinical lab measurements
5.have liver disease staging assessment as follows:
Absence of cirrhosis defined as follows
•Liver biopsy performed within 24 months of Day 1 of this study •Fibroscan performed within 12 months of Day 1 of this study with a result of ≤12.5 kPa
•Fibrosure® (Fibrotest®) score of ≤0.48 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) of ≤1 during Screening
Compensated cirrhosis is defined as any one of the following (Part B only):
•Liver biopsy performed prior to Day 1 of this study showing cirrhosis (F4)
•Fibroscan performed within 12 months of Day 1 of this study with a result >12.5 kPa
•FibroSure® (Fibrotest®) performed during Screening with a score of >0.75 and an aspartate aminotransferase (AST): platelet ratio index (APRI) of >2. APRI formula: AST÷lab upper limit of normal (ULN) for AST x 100÷ (platelet count÷100) (APRI calculation to be provided by the central laboratory.)
6.Have a prior treatment history of:
a.HCV treatment-naïve
b.Prior virologic failure after treatment with a Peg-IFN/RBV regimen
(Part B only):
i.P/R Null Responder: <2 log10 IU/mL reduction in HCV RNA after at least 12 weeks of a Peg-IFN/RBV regimen.
ii.P/R Partial Responder: ≥2 log10 IU/mL reduction in HCV RNA after at least 12 weeks of treatment, but not achieving HCV RNA target not detected at end-of-treatment, with a Peg-IFN/RBV regimen.
iii.P/R Relapser: HCV RNA target not detected at end-of-treatment with a Peg-IFN/RBV regimen, but HCV RNA quantifiable (≥LLOQ) during follow-up.
7.meet one of the following categories:
-subject is is not of reproductive potential
- subject is a female* or a male who is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner beginning at least 2 weeks prior to administration of the initial dose of study drug, and for 90 days after the last dose of study drug by complying with one of the following: (1) practice abstinence OR (2) use (or have their partner use) two forms of acceptable barrier contraception Acceptable methods of contraception are:
•oral contraceptives (Part B and C only)
•intrauterine device
•diaphragm with spermicide
•cervical cap with spermicide (nulliparous women only)
•contraceptive sponge with spermicide (nulliparous women only)
•male condom with spermicide or female condom with spermicide
If male, subjects must agree to use a condom with spermicide or abstain from sexual intercourse during the trial until 90 days after the last dose of trial drug.
8. understand the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate
9. provide written informed consent for the trial.
For Part B only:
For HIV coinfected subjects these additional criteria must also be met.
10. have HIV-1 infection documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test
11. meet one of the following criteria:
a.not currently be on ART and have no plans to initiate ART treatment
i.subjects not on ART must have CD4+ T-cell count >500 cells/mm3 at screening
b.have well controlled HIV on ART, defined as:
i.must have achieved virologic suppression on HIV ART at least 8 weeks prior to study entry
1.the ART regimen must contain only the following antiretroviral medications: tenofovir, abacavir, lamivudine, emtricitabine, raltegravir, dolutegravir and rilpivirine
2.dose modifications or changes in drugs during the 4 weeks prior to study entry are not permitted
ii.have HIV RNA <LLOQ at screening
iii.have not experienced virologic failure for at least 8 weeks prior to screening
iv.subjects on ART must have a CD4+ T-cell count >200 cells/mm3 at screening
12.have at least one viable antiretroviral regimen alternative beyond their current regimen
For Part C only:
13.Enrollment in Part C will be open only to subjects in Part A who relapse following completion of therapy
|
|
| E.4 | Principal exclusion criteria |
1. is under the age of legal consent, is mentally or legally incapacitated, has significant emotional problems or has a history of a clinically significant psychiatric disorder which would interfere with the study procedures
2.has evidence of decompensated liver disease.
3.For cirrhotics (Part B only):
a.subjects that are Child-Pugh Class B or C or who have a Pugh-Turcotte (CPT) score >5, must be excluded
4.coinfected with hepatitis B virus
5.coinfected with HIV (Part A only).
6.For subjects with HIV, has a history of opportunistic infection in the preceding 6 months prior to screening.
7.has a history of malignancy ≤5 years prior to signing informed consent.
8.has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC.
9.is taking or plans to take any of the prohibited medications listed in the protocol or is taking herbal supplements within 2 weeks of Day 1.
10.For Parts A and B only: is currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another such study during the course of this study.
11.has clinically-relevant drug or alchol abuse within 12 months of screening.
12.is a female and is pregnant or breast-feeding, or expecting to conceive or donate eggs from at least 2 weeks prior to Day 1 and 90 days after the last dose of study medication, or longer if dictated by local regulations. OR male subject who is expecting to donate sperm from at least 2 weeks prior to day 1 until 90 days after the last dose of study medication, or longer if dictated by local regulations.
13. Part C only: is a male whose female partner(s) is/are pregnant
14. has any of the following conditions:
a.Organ transplants other than cornea and hair.
b.Poor venous access that precludes routine peripheral blood sampling required for this trial.
c.subject with a history of gastric surgery or subject with a history of malabsorption disorders.
d.Current or history of any clinically significant cardiac abnormalities/dysfunction, including but not limited to: angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia, uncontrolled hypertension, a history of use of antianginal or anti-arrhythmic agents for cardiac conditions, prolonged ECG QTc interval (>470 ms for males or >480 ms for females by either the Fridericia formula) at the screening visit, personal or family history of Torsade de pointes.
e.Chronic pulmonary disease, including but not limited to: clinically significant chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis.
f. Part C only: Haemoglobinopathy, including but not limited to thalassaemia major.
g.CNS trauma requiring intubation, intracranial pressure monitoring, brain meningeal or skull surgery, or resulting in seizure, coma, permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF) leak. Prior brain hemorrhage and/or intracranial aneurysms
h.Current or history of seizure disorder unless seizure was >10 years ago, a single isolated event, no history of or current use of anti-seizure medications, and a normal neurological examination is documented in trial files within 6 months of Day1.
i.History of stroke or transient ischemic attack.
j.History of a medical/surgical condition that resulted in hospitalization within the 3 months prior to enrollment, other than for minor elective procedures.
k.Medical/surgical conditions that may result in a need for hospitalization during the period of the study.
l.Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids, TNF antagonists, or other immunosuppressant drugs during the course of the trial.
m.has any condition, prestudy laboratory or ECG abnormality or history of any illness, which might confound the results of the study or pose additional risk in administering the study drugs to the subject.
n.had a life-threatening SAE during the screening period.
o.has evidence of history of chronic hepatitis not caused by HCV
15. has exclusionary laboratory values at the screening visit as listed in Table 7.
16. For Part C only:
a, b, c) Experience virologic rebound, virologic breakthrough or confirmed HCV RNA≥ LLOQ while on treatment after being < LLOQ previously.
d) Meet other exclusion criteria 1-15, as outlined above. |
|
| E.5 End points |
| E.5.1 | Primary end point(s) |
| The primary efficacy endpoint will be the proportion of subjects achieving SVR12 in each treatment arm. |
|
| E.5.1.1 | Timepoint(s) of evaluation of this end point |
| 12 weeks after completion of therapy |
|
| E.5.2 | Secondary end point(s) |
| The primary efficacy endpoint will be the proportion of subjects achieving SVR24 in each treatment arm. |
|
| E.5.2.1 | Timepoint(s) of evaluation of this end point |
| 24 weeks after completion of therapy |
|
| E.6 and E.7 Scope of the trial |
| E.6 | Scope of the trial |
| E.6.1 | Diagnosis | No |
| E.6.2 | Prophylaxis | No |
| E.6.3 | Therapy | Yes |
| E.6.4 | Safety | Yes |
| E.6.5 | Efficacy | Yes |
| E.6.6 | Pharmacokinetic | Yes |
| E.6.7 | Pharmacodynamic | No |
| E.6.8 | Bioequivalence | No |
| E.6.9 | Dose response | No |
| E.6.10 | Pharmacogenetic | No |
| E.6.11 | Pharmacogenomic | Yes |
| E.6.12 | Pharmacoeconomic | No |
| E.6.13 | Others | No |
| E.7 | Trial type and phase |
| E.7.1 | Human pharmacology (Phase I) | No |
| E.7.1.1 | First administration to humans | No |
| E.7.1.2 | Bioequivalence study | No |
| E.7.1.3 | Other | No |
| E.7.1.3.1 | Other trial type description | |
| E.7.2 | Therapeutic exploratory (Phase II) | Yes |
| E.7.3 | Therapeutic confirmatory (Phase III) | No |
| E.7.4 | Therapeutic use (Phase IV) | No |
| E.8 Design of the trial |
| E.8.1 | Controlled | Yes |
| E.8.1.1 | Randomised | Yes |
| E.8.1.2 | Open | Yes |
| E.8.1.3 | Single blind | No |
| E.8.1.4 | Double blind | No |
| E.8.1.5 | Parallel group | Yes |
| E.8.1.6 | Cross over | No |
| E.8.1.7 | Other | No |
| E.8.2 | Comparator of controlled trial |
| E.8.2.1 | Other medicinal product(s) | No |
| E.8.2.2 | Placebo | No |
| E.8.2.3 | Other | Yes |
| E.8.2.3.1 | Comparator description |
| MK-8742 versus MK-8408 (Part A only); no comparator in Part B |
|
| E.8.2.4 | Number of treatment arms in the trial | 9 |
| E.8.3 |
The trial involves single site in the Member State concerned
| No |
| E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
| E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
| E.8.5 | The trial involves multiple Member States | Yes |
| E.8.5.1 | Number of sites anticipated in the EEA | 44 |
| E.8.6 Trial involving sites outside the EEA |
| E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
| E.8.6.2 | Trial being conducted completely outside of the EEA | No |
| E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
| Australia |
| Canada |
| Denmark |
| France |
| Germany |
| Israel |
| Italy |
| New Zealand |
| Switzerland |
| United Kingdom |
| United States |
|
| E.8.7 | Trial has a data monitoring committee | No |
| E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
| E.8.9 Initial estimate of the duration of the trial |
| E.8.9.1 | In the Member State concerned years | 2 |
| E.8.9.1 | In the Member State concerned months | 5 |
| E.8.9.1 | In the Member State concerned days | 29 |
| E.8.9.2 | In all countries concerned by the trial years | 2 |
| E.8.9.2 | In all countries concerned by the trial months | 5 |
| E.8.9.2 | In all countries concerned by the trial days | 29 |
Print
